Programmed cell death ligand 1 as a biomarker in head and neck cancer
نویسندگان
چکیده
منابع مشابه
The genetic landscape of programmed death ligand‐1 (PD‐L1) alterations in head and neck cancer
OBJECTIVES Nivolumab has recently been shown in the phase III clinical trial CheckMate-141 to have superior survival rates compared to the current standard of care chemotherapy for recurrent or metastatic platinum-resistant head and neck squamous cell carcinoma (HNSCC). Nivolumab targets the immune inhibitory receptor programmed cell death 1 (PD-1). Programmed cell death ligand 1 (PD-L1) genomi...
متن کاملAntagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are the two important checkpoint molecules with great potential in targ...
متن کاملProgrammed Cell Death Ligand 1 Expression in Canine Cancer.
BACKGROUND Antibody therapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) is a promising therapy in human cancer, but only limited information on PD-L1 expression in canine tumors is available. MATERIALS AND METHODS PD-L1 expression was examined in 31 canine tumor cell lines of various origins by flow cytometry and western blotting, and in canine tumor an...
متن کاملClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.
PURPOSE The negative regulatory programmed death-1/programmed death-1 ligand (PD-1/PD-L) pathway in T-cell activation has been suggested to play an important role in tumor evasion from host immunity. In this study, we investigated the expression of PD-L1 and PD-L2 in human esophageal cancer to define their clinical significance in patients' prognosis after surgery. EXPERIMENTAL DESIGN PD-L1 a...
متن کاملChanges in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
Programmed death-ligand 1 (PD-L1) expression is regarded as a predictive marker for anti-PD-1/PD-L1 therapy. The purpose of study was to explore the changes in PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) during treatment. Paired HNSCC tissues prior to and after cisplatin-based treatment were evaluated to determine PD-L1 protein expression by immunohistochemistry. Among the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Cytopathology
سال: 2017
ISSN: 1934-662X
DOI: 10.1002/cncy.21872